论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Liu Y, He A, Liu B, Zhong Y, Liao X, Yang J, Chen J, Wu J, Mei H
Received 16 October 2017
Accepted for publication 4 January 2018
Published 1 March 2018 Volume 2018:11 Pages 1121—1139
DOI https://doi.org/10.2147/OTT.S154211
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Amy Norman
Peer reviewer comments 4
Editor who approved publication: Dr Yao Dai
Abstract: Several
epidemiological studies have reported that polymorphisms in microRNA-196a2
(miR-196a2) were associated with various cancers. However, the results remained
unverified and were inconsistent in different cancers. Therefore, we carried
out an updated meta-analysis to elaborate the effects of rs11614913
polymorphism on cancer susceptibility. A total of 84 articles with 35,802 cases
and 41,541 controls were included to evaluate the association between the miR-196a2
rs11614913 and cancer risk by pooled odds ratios (ORs) and 95% confidence
intervals (CIs). The results showed that miR-196a2 rs11614913 polymorphism is
associated with cancer susceptibility, especially in lung cancer (homozygote
comparison, OR =0.840, 95% CI =0.734–0.961; recessive model, OR =0.858,
95% CI =0.771–0.955), hepatocellular carcinoma (allelic contrast,
OR =0.894, 95% CI =0.800–0.998; homozygote comparison,
OR =0.900, 95% CI =0.813–0.997; recessive model, OR =0.800, 95%
CI =0.678–0.944), and head and neck cancer (allelic contrast,
OR =1.076, 95% CI =1.006–1.152; homozygote comparison,
OR =1.214, 95% CI =1.043–1.413). In addition, significant association
was found among Asian populations (allele model, OR =0.847, 95%
CI =0.899–0.997, P =0.038; homozygote
model, OR =0.878, 95% CI =0.788–0.977, P =0.017; recessive model,
OR =0.895, 95% CI =0.824–0.972, P =0.008)
but not in Caucasians. The updated meta-analysis confirmed the previous results
that miR-196a2 rs11614913 polymorphism may serve as a risk factor for patients
with cancers.
Keywords: miR-196a2, polymorphisms, cancer risk, meta-analysis